Public trading strategy
This FDA approval is a genuine category-defining milestone for Moderna — it prov
Created
Thesis
This FDA approval is a genuine category-defining milestone for Moderna — it proves the mRNA platform works beyond COVID and opens the door to seasonal flu shots, a market that is vastly larger and more recurring than pandemic-era COVID doses. Moderna's stock had been beaten down on post-COVID revenue decline, so this approval provides both a fundamental catalyst and a potential sentiment reversal. The news is fresh and concrete, meaning the market is still digesting the implications, which typically leads to a multi-day follow-through as analysts revise models and price targets upward.
Strategy approach
This FDA approval is a genuine category-defining milestone for Moderna — it proves the mRNA platform works beyond COVID and opens the door to seasonal flu shots, a market that is vastly larger and more recurring than pandemic-era COVID doses. Moderna's stock had been beaten down on post-COVID revenue decline, so this approval provides both a fundamental catalyst and a potential sentiment reversal. The news is fresh and concrete, meaning the market is still digesting the implications, which typically leads to a multi-day follow-through as analysts revise models and price targets upward. Decision analysis profile: near_term. Required dimensions: as_of_session, catalyst_timing, expectations_priced_in, price_volume, liquidity_spread_volatility, dilution_capital_allocation, downside,…
Markets and timeframes
MRNA1D
Latest published rule evaluation
Evaluated . This is a dated rule snapshot, not a live price or trade execution confirmation.
MRNA · 1d
1 of 3 published entry conditions marked met.
- Price crossed above EMA (50) — far
- EMA (9) crossed above EMA (21) — far
- Price above EMA (50) — met
- Price crossed above Bollinger (20) — far
- Price crossed below EMA (50) — far
Entry and exit at a glance
These are the named rules in the shared configuration. Review the full conditions below before using a strategy.
- Entry: Pullback-and-Reclaim Long on Rising 50d EMA Support (MRNA@1d) (3 conditions)
- Exit: Time Stop at 60 Trading Days Without Follow-Through (1 condition)
- Exit: TP: Scale Out at Prior Swing High / Resistance[1] (MRNA@1d) (1 condition)
- Exit: TP: Overextended Above Upper Volatility Band (MRNA@1d) (1 condition)
- Exit: SL: Closing Basis Break of 50d EMA Support Proxy (MRNA@1d) (1 condition)
Shared strategy rules
Rule configuration
{
"data_dependencies": [
{
"symbol": "STOCK:MRNA",
"timeframe": "1d"
}
],
"entry_rules": [
{
"conditions": [
{
"left": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"field": "close",
"type": "price"
},
"operator": "crossed_above",
"right": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"indicator": {
"name": "ema",
"period": 50
},
"type": "indicator"
}
},
{
"left": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"indicator": {
"name": "ema",
"period": 9
},
"type": "indicator"
},
"operator": "crossed_above",
"right": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"indicator": {
"name": "ema",
"period": 21
},
"type": "indicator"
}
},
{
"left": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"field": "close",
"type": "price"
},
"operator": "greater_than",
"right": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"indicator": {
"name": "ema",
"period": 50
},
"type": "indicator"
}
}
],
"direction": "long",
"enabled": true,
"id": "entry_1",
"name": "Pullback-and-Reclaim Long on Rising 50d EMA Support (MRNA@1d)",
"priority": 1,
"trade_symbol": "STOCK:MRNA"
}
],
"exit_rules": [
{
"applies_to": "both",
"conditions": [
{
"left": {
"field": "holding_period_bars",
"type": "position"
},
"operator": "greater_than_or_equal",
"right": {
"type": "constant",
"value": 60
}
}
],
"enabled": true,
"id": "exit_1",
"name": "Time Stop at 60 Trading Days Without Follow-Through",
"priority": 1,
"purpose": "signal"
},
{
"applies_to": "both",
"conditions": [
{
"left": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"field": "close",
"type": "price"
},
"operator": "greater_than_or_equal",
"right": {
"rank": 1,
"type": "resistance_level"
}
}
],
"enabled": true,
"id": "exit_2",
"name": "TP: Scale Out at Prior Swing High / Resistance[1] (MRNA@1d)",
"priority": 97,
"purpose": "take_profit",
"target_symbol": "STOCK:MRNA"
},
{
"applies_to": "both",
"conditions": [
{
"left": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"field": "close",
"type": "price"
},
"operator": "crossed_above",
"right": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"field": "upper",
"indicator": {
"name": "bollinger_bands",
"period": 20,
"std_dev": 2
},
"type": "indicator"
}
}
],
"enabled": true,
"id": "exit_3",
"name": "TP: Overextended Above Upper Volatility Band (MRNA@1d)",
"priority": 98,
"purpose": "take_profit"
},
{
"applies_to": "long",
"conditions": [
{
"left": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"field": "close",
"type": "price"
},
"operator": "crossed_below",
"right": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"indicator": {
"name": "ema",
"period": 50
},
"type": "indicator"
}
}
],
"enabled": true,
"id": "exit_4",
"name": "SL: Closing Basis Break of 50d EMA Support Proxy (MRNA@1d)",
"priority": 100,
"purpose": "stop_loss"
}
],
"position_sizing": {
"max_position_percent": 25,
"method": {
"risk_percent": 2,
"support_stop_rank": 1,
"type": "fixed_risk"
},
"min_position_value": 100
},
"trigger_timeframe": "1d",
"version": 2
}Indicator configuration
{
"indicators": [
{
"name": "ema",
"period": 9
},
{
"name": "ema",
"period": 21
},
{
"name": "ema",
"period": 50
},
{
"name": "ema",
"period": 100
},
{
"name": "adx",
"period": 14
},
{
"name": "bollinger_bands",
"period": 20,
"std_dev": 2
}
]
}Parsed strategy
{
"data_dependencies": [
{
"symbol": "STOCK:MRNA",
"timeframe": "1d"
}
],
"entry_rules": [
{
"conditions": [
{
"left": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"field": "close",
"type": "price"
},
"operator": "crossed_above",
"right": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"indicator": {
"name": "ema",
"period": 50
},
"type": "indicator"
}
},
{
"left": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"indicator": {
"name": "ema",
"period": 9
},
"type": "indicator"
},
"operator": "crossed_above",
"right": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"indicator": {
"name": "ema",
"period": 21
},
"type": "indicator"
}
},
{
"left": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"field": "close",
"type": "price"
},
"operator": "greater_than",
"right": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"indicator": {
"name": "ema",
"period": 50
},
"type": "indicator"
}
}
],
"direction": "long",
"enabled": true,
"id": "entry_1",
"name": "Pullback-and-Reclaim Long on Rising 50d EMA Support (MRNA@1d)",
"priority": 1,
"trade_symbol": "STOCK:MRNA"
}
],
"exit_rules": [
{
"applies_to": "both",
"conditions": [
{
"left": {
"field": "holding_period_bars",
"type": "position"
},
"operator": "greater_than_or_equal",
"right": {
"type": "constant",
"value": 60
}
}
],
"enabled": true,
"id": "exit_1",
"name": "Time Stop at 60 Trading Days Without Follow-Through",
"priority": 1,
"purpose": "signal"
},
{
"applies_to": "both",
"conditions": [
{
"left": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"field": "close",
"type": "price"
},
"operator": "greater_than_or_equal",
"right": {
"rank": 1,
"type": "resistance_level"
}
}
],
"enabled": true,
"id": "exit_2",
"name": "TP: Scale Out at Prior Swing High / Resistance[1] (MRNA@1d)",
"priority": 97,
"purpose": "take_profit",
"target_symbol": "STOCK:MRNA"
},
{
"applies_to": "both",
"conditions": [
{
"left": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"field": "close",
"type": "price"
},
"operator": "crossed_above",
"right": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"field": "upper",
"indicator": {
"name": "bollinger_bands",
"period": 20,
"std_dev": 2
},
"type": "indicator"
}
}
],
"enabled": true,
"id": "exit_3",
"name": "TP: Overextended Above Upper Volatility Band (MRNA@1d)",
"priority": 98,
"purpose": "take_profit"
},
{
"applies_to": "long",
"conditions": [
{
"left": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"field": "close",
"type": "price"
},
"operator": "crossed_below",
"right": {
"chart_ref": {
"symbol": "STOCK:MRNA",
"timeframe": "1d"
},
"indicator": {
"name": "ema",
"period": 50
},
"type": "indicator"
}
}
],
"enabled": true,
"id": "exit_4",
"name": "SL: Closing Basis Break of 50d EMA Support Proxy (MRNA@1d)",
"priority": 100,
"purpose": "stop_loss"
}
],
"position_sizing": {
"max_position_percent": 25,
"method": {
"risk_percent": 2,
"support_stop_rank": 1,
"type": "fixed_risk"
},
"min_position_value": 100
},
"trigger_timeframe": "1d",
"version": 2
}Strategy instructions
Trading agent generated from recommendation idea 'This FDA approval is a genuine category-defining milestone for Moderna — it proves the mRNA platform works beyond COVID and opens the door to seasonal flu shots, a market that is vastly larger and more recurring than pandemic-era COVID doses. Moderna's st'. Thesis: This FDA approval is a genuine category-defining milestone for Moderna — it proves the mRNA platform works beyond COVID and opens the door to seasonal flu shots, a market that is vastly larger and more recurring than pandemic-era COVID doses. Moderna's stock had been beaten down on post-COVID revenue decline, so this approval provides both a fundamental catalyst and a potential sentiment reversal. The news is fresh and concrete, meaning the market is still digesting the implications, which typically leads to a multi-day follow-through as analysts revise models and price targets upward.
Performance
No trade count, win rate, or realized P&L figures are provided in this public preview. The thesis and shared rules do not establish a performance record.
What this public preview can establish
- The dated rule snapshot above shows the conditions evaluated at that time. It does not prove a current trigger or executed trade.
- Technical strategy fields are shared above. Inspect the actual conditions and check when they were evaluated before relying on them.
- No trade count, win rate, or P&L figure is published in this preview. It cannot establish a performance record.
Explore
How CommonQuant researches and tests strategies · Public paper-trading record and its limits · Discover public strategies